Angioplasty in acute myocardial infarction after low-dose alteplase and abciximab in transferred patients. A comparison with pimary angioplasty on site

Italian Heart Journal

Volumn 4, Issue 5, 2003, Pages 311-317

  Manari, Antonio ^a   Guiducci, Vincenzo ^a   Muià, Nicola ^a   Giacometti, Paola ^a   Fioroni, Stefano ^a   Navazio, Alessandro ^b   Gambarati, Gianpaolo ^b   Bendinelli, Stefano ^b   Bruno, Gabriele ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b PATHOLOGY UNIT   (Italy)

Author keywords

Coronary angioplasty; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ATROPINE; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEATH; DEFIBRILLATION; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEALTH CENTER; HEART CATHETERIZATION; HEART REINFARCTION; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; PATIENT REFERRAL; PATIENT TRANSPORT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; SAFETY; ST SEGMENT; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; REOPERATION; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TRANSPORTATION OF PATIENTS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0242299746     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-8.
2. Zahn R, Schiele R, Seidl K, et al. Primary percutaneous transluminal coronary angioplasty for acute myocardial infarction in patients not included in randomized studies. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Am J Cardiol 1999; 83: 1314-9.
3. Ribichini F, Steffenino G, Dellavalle A, et al. Emergency angioplasty in high-risk acute infarct. G Ital Cardiol 1995; 25: 707-14.
4. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 967-72.
5. Parmley WW. Cost-effectiveness of reperfusion strategies. Am Heart J 1999; 138 (Part 2): S142-S152.
6. Kastrati A, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. J Am Coll Cardiol 1998; 32: 970-6.
7. Zijlstra F, van't Hof AW, Liem AL, Hoorntje JC, Suryapranata H, de Boer MJ. Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart 1997; 78: 333-6.
8. Brodie BR, Stuckey TD, Hansen CJ, et al. Effect of treatment delay on outcomes in patients with acute myocardial infarction transferred from community hospitals for primary percutaneous coronary intervention. Am J Cardiol 2002; 89: 1243-7.
9. Liem AL, van't Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1998; 32: 629-33.
10. Gibson CM. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med 1999; 130: 841-7.
11. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol 2000; 36: 1489-96.
12. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-8.
13. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197-203.
14. Ahmad T, Webb JG, Carere RR, Dodek A. Coronary stenting for acute myocardial infarction. Am J Cardiol 1995; 76: 77-80.
15. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998; 31: 1234-9.
16. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol 1998; 31: 294-300.
17. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
18. van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33: 1528-32.
19. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720-32.
20. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-6.
21. de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Am J Cardiol 2000; 85: 299-304.
22. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
23. Danzi GB. Attività nei laboratori di emodinamica italiani nel 2000. Emodinamica 2001; 24: 8-9.
24. Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every NR. Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2000; 35: 371-9.
25. Widimsky P, Budesinsky T, Vorac D, et al, for the PRAGUE Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomised national multicentre trial - PRAGUE-2. Eur Heart J 2003; 24: 94-104.
26. Margheri M, Meucci F, Falai M, et al. Transferring patients for direct coronary angioplasty: a retrospective analysis of 135 unselected patients with acute myocardial infarction. Ital Heart J 2001; 2: 921-6.
27. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82: 426-31.
28. Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
29. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
30. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13-8.
31. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-41.
32. Widimsky P, Groch L, Zeliko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomised trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterisation laboratory. The PRAGUE study. Eur Heart J 2000; 21: 823-31.
33. Loubeyre C, Lefevre T, Louvard Y, et al. Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. Eur Heart J 2001; 22: 1128-35.
34. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT Investigators. Plasminogen-Activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999; 34: 1954-62.
35. Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
36. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-94.